PMID: 9450805Feb 5, 1998Paper

Telomerase activity in acute myelogenous leukaemia: clinical and biological implications

British Journal of Haematology
J G SeolY Y Lee

Abstract

We examined telomerase activity in myeloid leukaemic cell lines, normal haemopoietic cells, and leukaemic blasts from acute myelogenous leukaemia (AML) patients. Normal bone marrow mononuclear (BMNC) cells expressed low telomerase activity. Higher telomerase activity was detected in 10 myeloid leukaemic cell lines compared to normal BMNC cells. Treatment with 1,25(OH)2D3, and vitamin D3 analogues, EB1089 and KH1060, reduced telomerase activity in vitamin D3-sensitive HL-60 cells, whereas vitamin D3 insensitive K562 cells did not change its activity. This down-regulation of telomerase activity by EB1089 was associated with induction of p21 protein. The rank order of telomerase activity was leukaemic CD34- cells > leukaemic CD34+ cells > normal CD34- cells > normal CD34+ cells. Telomerase activity was positive in all of the AML patients tested; however, heterogeneity of telomerase activity was found amongst this group. Therefore we compared telomerase activity with clinical response. Unexpectedly, we found that a higher rate of complete remission was noted in AML patients with higher telomerase activity. No association between telomerase activity and biological parameters including percentage of S-phase, cytotoxicity to cytosine ...Continue Reading

References

Nov 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·R C AllsoppC B Harley
Jun 1, 1992·Trends in Genetics : TIG·W E Wright, J W Shay
Jun 20, 1992·Journal of Molecular Biology·M Z LevyC B Harley
Apr 18, 1991·Nature·E H Blackburn
Feb 1, 1990·Molecular and Cellular Biology·T de LangeH E Varmus
May 31, 1990·Nature·C B HarleyC W Greider
Oct 18, 1972·Nature: New Biology·J D Watson
Dec 1, 1995·American Journal of Hematology·D A VolpeE C Kohn
Sep 26, 1995·Proceedings of the National Academy of Sciences of the United States of America·D BroccoliT de Lange
Jan 1, 1994·Cold Spring Harbor Symposia on Quantitative Biology·C B HarleyC W Greider
Jun 21, 1995·Journal of the National Cancer Institute·M S Rhyu
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·T de Lange
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·C M CounterC B Harley
Apr 1, 1993·Trends in Genetics : TIG·B Vogelstein, K W Kinzler
Dec 19, 1995·Proceedings of the National Academy of Sciences of the United States of America·H W SharmaR Narayanan
Jun 1, 1996·Molecular and Cellular Biology·S E HoltJ W Shay
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·X ZhuR Narayanan
Jun 1, 1996·The Journal of Experimental Medicine·N P WengR J Hodes
Sep 13, 1996·Biochemical and Biophysical Research Communications·E SavoyskyM Tsuchiya
Dec 1, 1996·Leukemia & Lymphoma·B Leber, S Bacchetti

❮ Previous
Next ❯

Citations

Feb 23, 2008·International Journal of Hematology·Ozgur CoguluFerda Ozkinay
Mar 21, 2002·Journal of Pediatric Hematology/oncology·Shawn E HoltAlvin Zipursky
Mar 23, 2006·The American Journal of Chinese Medicine·Wan-Zhuo XieZhen Cai
Apr 28, 2000·Leukemia & Lymphoma·B LiH D Preisler
May 19, 2007·Stem Cells·Mark W DrummondTim H Brummendorf
Dec 24, 2011·Cancer Letters·Minji KimMaurizio Chiriva-Internati
Jul 27, 2005·American Journal of Hematology·Hee Jin HuhWha Soon Chung

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.